GreenLight Biosciences, Samsung Biologics collaborate on COVID-19 mRNA vaccine manufacturing
Samsung Biologics will collaborate with GreenLight Biologics to manufacture an mRNA COVID-19 vaccine candidate at a commercial scale. The partnership aims to accelerate production of GreenLight's COVID-19 vaccine candidate for phase III clinical trials, subject to regulatory approval. Read More
Technology upgrades needed to address future pandemics, GAO report says
Vaccine R&D and manufacturing face many challenges despite the success of COVID-19 vaccines. This is according to a new U.S. Government Accountability Office (GAO) report. Read More
FDA expands EUA for Pfizer, Moderna COVID-19 vaccine boosters
The U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) for booster shots of both the Pfizer-BioNTech COVID-19 vaccine and the Moderna COVID-19 vaccine to include individuals 18 and older. Read More
5 takeaways from SITC 2021
WASHINGTON, DC - The Society for Immunotherapy of Cancer's (SITC) 2021 annual meeting November 10-14 was a successful gathering of research and clinical experts focused on the development of innovative cancer treatments. The ScienceBoard team was live onsite at the event. Editor in Chief Samantha Black, PhD, shared five takeaways from the meeting. Read More
Innovation and safety remain key amid shifting pandemic-impacted clinical trial protocols
WASHINGTON, DC - During the pandemic, clinical trial execution for cancer therapies has been challenging, said Dr. Samit Hirawat, chief medical officer at Bristol Myers Squibb, at the Society for Immunotherapy of Cancer's 2021 annual meeting. Despite the challenges presented by the pandemic, Hirawat noted that stakeholders held patient safety and innovation as key priorities. Hirawat spoke with ScienceBoard onsite at the meeting. Read More
Where is the immunotherapy field headed after COVID-19?
WASHINGTON, DC - Best known for his contributions to the Moderna COVID-19 vaccine, former Moderna chief medical officer, Dr. Tal Zaks, PhD, chaired a session on RNA vaccines at the Society for Immunotherapy of Cancer's (SITC) 2021 annual meeting. Zaks shared his perspectives and hopeful outlook with ScienceBoard at the meeting. Read More
Is the accelerated approval process working for cancer immunotherapies?
WASHINGTON, DC - Leveraging years of experience, Dr. Alessandra Cesano, PhD, who serves on the board of directors of the Society for Immunotherapy of Cancer (SITC), chaired a panel discussion on the accelerated approval process for cancer immunotherapies at the organization’s 2021 annual meeting. Cesano spoke with ScienceBoard at the meeting. Read More
Twist launches new biotech firm
Twist Bioscience has launched a new biotechnology firm, Revelar Biotherapeutics, to develop and market an antibody discovered by Twist that neutralizes SARS-CoV-2. Read More
EY white paper details how the CGT industry can collaborate to advance the field
A transition from corporate individualism to teamwork and collaboration is necessary to meet the challenges that exist for companies in the cell and gene therapy (CGT) industry, according to a new white paper published by Ernst & Young (EY) on November 4. Read More
Amyris, ImmunityBio partner on COVID-19 vaccine
Synthetic biotechnology firm Amyris and immunotherapy company ImmunityBio have partnered to accelerate the commercialization of a COVID-19 RNA vaccine. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter